Francesco Sclafani

3.7k total citations
121 papers, 1.9k citations indexed

About

Francesco Sclafani is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Francesco Sclafani has authored 121 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Oncology, 48 papers in Surgery and 36 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Francesco Sclafani's work include Colorectal Cancer Treatments and Studies (57 papers), Colorectal and Anal Carcinomas (38 papers) and Colorectal Cancer Surgical Treatments (29 papers). Francesco Sclafani is often cited by papers focused on Colorectal Cancer Treatments and Studies (57 papers), Colorectal and Anal Carcinomas (38 papers) and Colorectal Cancer Surgical Treatments (29 papers). Francesco Sclafani collaborates with scholars based in United Kingdom, Belgium and Spain. Francesco Sclafani's co-authors include David Cunningham, Ian Chau, Clare Peckitt, Elizabeth Smyth, Alain Hendlisz, Lorenza Rimassa, Armando Santoro, Giacomo Bregni, Gina Brown and Carlo Carnaghi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Francesco Sclafani

111 papers receiving 1.9k citations

Peers

Countries citing papers authored by Francesco Sclafani

Since Specialization

Citations

This map shows the geographic impact of Francesco Sclafani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Sclafani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Sclafani more than expected).

Fields of papers citing papers by Francesco Sclafani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Sclafani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Sclafani. The network helps show where Francesco Sclafani may publish in the future.

Co-authorship network of co-authors of Francesco Sclafani

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Sclafani. A scholar is included among the top collaborators of Francesco Sclafani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Sclafani. Francesco Sclafani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and Validation of an ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography–Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal Cancer 2025 ·JCO Clinical Cancer Informatics ·(unknown), Jennifer Dhont, Thomas Guiot, Hugo Levillain, (unknown), (unknown), Francesco Sclafani, Patrick Flamen, N. Reynaert, (unknown), Alain Hendlisz	0
2	Retrospective Evaluation of the Prognostic Value of Histological Growth Pattern in Patients with Colorectal Peritoneal Metastases Undergoing Curative-Intent Cytoreductive Surgery 2024 ·Annals of Surgical Oncology ·(unknown), (unknown), Pieter Demetter, (unknown), (unknown), Francesco Sclafani, Vincent Donckier, (unknown), Gabriel Liberale	1
3	505P State of the art of gastrointestinal (GI) cancer trials for older patients (pts): A systematic review (SR) 2024 ·Annals of Oncology ·(unknown), (unknown), Everardo D. Saad, Giacomo Bregni, (unknown), Valentina Daprà, Chiara Conti, (unknown), (unknown), (unknown), (unknown), J-L. van Laethem, Francesco Sclafani	1
4	143P Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype 2024 ·Annals of Oncology ·(unknown), (unknown), David Tougeron, (unknown), Simon Pernot, Thibault Mazard, Vincent Hautefeuille, Méher Ben Abdelghani, (unknown), Romain Cohen, Francesco Sclafani, Marie Müller, (unknown), Clélia Coutzac, Antoine Hollebecque, (unknown), Philippe Parent, Julien Taı̈eb, Rosine Guimbaud, J. Selves	1
5	Pre-trial quality assurance of diffusion-weighted MRI for radiomic analysis and the role of harmonisation 2022 ·Physica Medica ·(unknown), Shih‐Li Chao, Giacomo Bregni, (unknown), Thomas Guiot, Jennifer Dhont, Ákos Gulybán, (unknown), Francesco Sclafani, N. Reynaert, Maria Antonietta Bali	5
6	Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 2021 ·Cancers ·Nicola Personeni, Valeria Smiroldo, Emilio Francesco Giunta, (unknown), Lorenza Rimassa, Giacomo Bregni, Francesco Sclafani	14
7	Leukemia Inhibitory Factor: A Potential Biomarker and Therapeutic Target in Pancreatic Cancer 2021 ·Archivum Immunologiae et Therapiae Experimentalis ·(unknown), Piotr Potemski, Francesco Sclafani, Maciej Borowiec	19
8	Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group 2021 ·British Journal of Cancer ·Thibaud Koessler, María Alsina, Dirk Arnold, Irit Ben‐Aharon, Manfred P. Lutz, Radka Obermannová, Marc Peeters, Francesco Sclafani, Elizabeth Smyth, Juan W. Valle, Dorothea Wagner, Lucjan Wyrwicz, Elisa Fontana, Markus Moehler	3
9	Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer 2020 ·BMJ Open Gastroenterology ·(unknown), Pieter Demetter, (unknown), María Gómez Galdón, (unknown), (unknown), Ligia Craciun, (unknown), Denis Larsimont, Tom Lenaerts, Francesco Sclafani, Amélie Deleporte, Vincent Donckier, Alain Hendlisz, Caroline Vandeputte	4
10	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes 2019 ·Scientific Reports ·Chanthirika Ragulan, Katherine Eason, Elisa Fontana, Gift Nyamundanda, Noelia Tarazona, Yatish Patil, Pawan Poudel, Rita T. Lawlor, Maguy Del Rio, Si‐Lin Koo, (unknown), Francesco Sclafani, Ruwaida Begum, Larissa Mendes, Pierre Martineau, Aldo Scarpa, Andrés Cervantes, Iain Beehuat Tan, David Cunningham, Anguraj Sadanandam	29
11	New therapeutic targets in pancreatic cancer 2019 ·Cancer Treatment Reviews ·Eleonora Lai, Marco Puzzoni, Pina Ziranu, Andrea Pretta, (unknown), Stefano Mariani, Nicole Liscia, (unknown), (unknown), Mara Persano, Clelia Donisi, (unknown), (unknown), Annagrazia Pireddu, Laura Demurtas, Valeria Pusceddu, Silvia Camera, Francesco Sclafani, Mario Scartozzi	76
12	InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial 2018 ·Annals of Oncology ·Sheela Rao, Francesco Sclafani, Cathy Eng, Marianne G. Guren, Richard Adams, Al B. Benson, David Sebag‐Montefiore, Eva Segelov, Annette Bryant, Clare Peckitt, (unknown), Michel Seymour, Jack Welch, Mark Saunders, R. Muirhead, John Bridgewater, Stephen Falk, Rob Glynne‐Jones, Dirk Arnold, David Cunningham	16
13	Multiplatform assay to classify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples into molecular subtypes with mutational profiles 2017 ·Annals of Oncology ·Elisa Fontana, Chanthirika Ragulan, David Cunningham, Sanna Hulkki-Wilson, Francesco Sclafani, Gift Nyamundanda, Katherine Eason, Ruwaida Begum, Irene Chong, Clare Peckitt, Maria Antonietta Bali, J. Oates, David Watkins, Shuan Rao, Michael Hubank, Andrew Wotherspoon, Nicola Valeri, Ian Chau, Naureen Starling, Anguraj Sadanandam	1
14	KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial 2016 ·Annals of Oncology ·Francesco Sclafani, Ian Chau, David Cunningham, (unknown), (unknown), Andrea Lampis, Chiara Braconi, (unknown), David González de Castro, Andrew Wotherspoon, Jaume Capdevila, (unknown), Andrés Cervantes, Ruwaida Begum, Hazel Lote, Giulia Mentrasti, Jens C. Hahne, Diana Tait, Gina Brown, Nicola Valeri	1
15	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer 2016 ·Annals of Oncology ·Francesco Sclafani, Gina Brown, David Cunningham, Andrew Wotherspoon, Diana Tait, Clare Peckitt, Jessica Evans, Shun Yu, Larissa Mendes, Josep Tabernero, Bengt Glimelius, Andrés Cervantes, Janet Thomas, Ruwaida Begum, J. Oates, Ian Chau	54
16	A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer 2015 ·JNCI Journal of the National Cancer Institute ·Francesco Sclafani, Tae‐Yop Kim, David Cunningham, Tae W. Kim, Josep Tabernero, Hans‐Joachim Schmoll, Jae Kyung Roh, Sun Kim, Young Shin Park, Tormod Kyrre Guren, Eliza A. Hawkes, (unknown), David Ferry, Jan‐Erik Frödin, Mark Ayers, Michael Nebozhyn, Clare Peckitt, Andrey Loboda, David J. Mauro, David Watkins	73
17	TP53 status may predict benefit from cetuximab in high-risk, locally advanced rectal cancer: Results of the EXPERT-C trial 2013 ·European Journal of Cancer ·Francesco Sclafani, D. González, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Josep Tabernero, Bengt Glimelius, Andrés Cervantes, Gina Brown, Ian Chau	5
18	Updated survival analysis of EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab in MRI-defined high risk rectal cancer patients 2013 ·European Journal of Cancer ·Francesco Sclafani, David Cunningham, Josep Tabernero, Bengt Glimelius, Andrés Cervantes, Clare Peckitt, (unknown), Gina Brown, David González de Castro, Ian Chau	3
19	Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy 2010 ·European Journal of Cancer ·Armando Santoro, Lorenza Rimassa, Alberto Sobrero, Giovanni Citterio, Francesco Sclafani, Carlo Carnaghi, Anna Pessino, Francesco Caprioni, (unknown), Maria Chiara Tronconi, Giovanna Finocchiaro, (unknown), (unknown), (unknown), (unknown), Catia Traversari, Federico Caligaris‐Cappio, A. Lambiase, Claudio Bordignon	40
20	Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer 2010 ·Chemotherapy ·Francesco Sclafani, Carlo Carnaghi, Piergiuseppe Colombo, Silvia Bozzarelli, Fabio De Vincenzo, Lorenza Rimassa, (unknown), Armando Santoro	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact